Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Xing‐Sheng Hu"'
Autor:
Hao‐Hua Zhu, Yu‐Tao Liu, Yu Feng, Li‐Na Zhang, Tong‐Mei Zhang, Gui‐Lan Dong, Pu‐Yuan Xing, Hong‐Yu Wang, Yuan‐Kai Shi, Xing‐Sheng Hu
Publikováno v:
Thoracic Cancer, Vol 12, Iss 20, Pp 2749-2757 (2021)
Abstract Background The aim of the study was to define the clinical significance of circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer (SCLC) patients. Methods CTCs/CTECs and their
Externí odkaz:
https://doaj.org/article/ba1392378a6b49439a6024ac353ddee1
Autor:
Li‐Ling Huang, Xing‐Sheng Hu, Yan Wang, Jun‐Ling Li, Hong‐Yu Wang, Peng Liu, Jian‐Ping Xu, Xiao‐Hui He, Xue‐Zhi Hao, Pei‐Di Jiang, Yu‐Tao Liu, Jian Luo, Sheng‐Yu Zhou, Jin‐Wan Wang, Jian‐Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuan‐Kai Shi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 13, Pp 1943-1951 (2021)
Abstract Background Extensive‐stage small cell lung cancer (ES‐SCLC) is deemed as a fatal malignancy with a poor prognosis. Although immunotherapy has gradually played an important role in the treatment of ES‐SCLC since 2018, ES‐SCLC treatmen
Externí odkaz:
https://doaj.org/article/65e0ed518d234253975ff03a2495a690
Autor:
Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently l
Externí odkaz:
https://doaj.org/article/a0304755a1dc4eaf9b7018977d22936b
Autor:
Jia-Ni Wang, Quan-Hui Qiao, Xing-Sheng Hu, Yu-Tao Liu, Zhi-Jie Wang, Jian-Chun Duan, Yu Feng, Hao-Hua Zhu, Li-Shao Guo
Publikováno v:
Chinese Medical Journal, Vol 134, Iss 17, Pp 2119-2121 (2021)
Externí odkaz:
https://doaj.org/article/42ffb9d621484050a38f3d1f4bc5b0e3
Publikováno v:
Chinese Medical Journal, Vol 133, Iss 20, Pp 2456-2465 (2020)
Abstract. Immunotherapy has become the mainstay for lung cancer treatment, providing sustained therapeutic responses and improved prognosis compared with those obtained with surgery, chemotherapy, radiotherapy, and targeted therapy. It has the potent
Externí odkaz:
https://doaj.org/article/6c6ee6dfb50642cdb44c1d90838e9309
Autor:
Hong-Shuai Li, Jun-Ling Li, Xiang Yan, Hai-Yan Xu, Li-Qiang Zhou, Xing-Sheng Hu, Yu-Ying Wang, Si-Yu Lei, Yan Wang
Publikováno v:
J Thorac Dis
BACKGROUND: Dacomitinib is a first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on NSCLC with complex EGFR mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada72f3438ce700e5fa15d8a8f443546
https://doi.org/10.21037/jtd-21-1841
https://doi.org/10.21037/jtd-21-1841
Autor:
Hong-Shuai Li, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, Li-Qiang Zhou, Peng Liu, Yu-Ying Wang, Xing-Sheng Hu, Pu-Yuan Xing, Yan Wang
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5307
(1) Background: Afatinib has been approved for patients with non-small cell lung cancer (NSCLC) carrying major uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another second-generation tyrosine kinase inhibitor, has also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97948cd8ad596bffc9577d81ffc67450
Background: Rab25 was indicated to be involved in several human tumors. However, the clinical significance of Rab25 in hepatocellular carcinoma (HCC) was still unclear. The purpose of this study was to investigate the expression and prognostic value
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f080314cfd06f373c031e720e0de1a6
https://doi.org/10.21203/rs.3.rs-43510/v1
https://doi.org/10.21203/rs.3.rs-43510/v1
Autor:
Kai-Lin Tang, Qian Tang, Xing-Sheng Hu, Jing-Hong Shi, Xin-Jie Wang, Xu Wang, Ke Pu, Zhong-Qi Long
Publikováno v:
World Journal of Gastroenterology
AIM To investigate the diagnostic accuracy of FibroScan (FS) in detecting esophageal varices (EV) in cirrhotic patients. METHODS Through a systemic literature search of multiple databases, we reviewed 15 studies using endoscopy as a reference standar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b493cb8736aeebe4a198f6aecf25da4
https://doi.org/10.3748/wjg.v23.i2.345
https://doi.org/10.3748/wjg.v23.i2.345
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 35(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c1fe04b3da4bfe599897157f8752a2f
https://pubmed.ncbi.nlm.nih.gov/24257296
https://pubmed.ncbi.nlm.nih.gov/24257296